Search Results - "Verrou, Evgenia"

Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw by VAHTSEVANOS, Konstantinos, KYRGIDIS, Athanassios, PARASKEVOPOULOS, Panagiotis, ZERVAS, Konstantinos, ANTONIADES, Konstantinos, VERROU, Evgenia, KATODRITOU, Eirini, TRIARIDIS, Stefanos, ANDREADIS, Charalampos G, BOUKOVINAS, Ioannis, KOLOUTSOS, Georgios E, TELEIOUDIS, Zisis, KITIKIDOU, Kyriaki

“…The reported incidence of osteonecrosis of the jaw (ONJ) ranges from 0.94% to 18.6%. This cohort study aimed to calculate the incidence of and identify the…”
Get full text

HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control study by Diamanti, Ioanna, Fylaktou, Asimina, Verrou, Evgenia, Vlachaki, Efthimia, Sinakos, Manolis, Katodritou, Eirini, Ouranos, Konstantinos, Minti, Fani, Gioula, Georgia

“…Human leukocyte antigen (HLA) polymorphisms have been associated with the development of various autoimmune diseases, as well as malignant neoplasms…”
Get full text

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma by BADROS, Ashraf, TERPOS, Evangelos, KATODRITOU, Eirini, GOLOUBEVA, Olga, KASTRITIS, Efstathios, VERROU, Evgenia, ZERVAS, Kostas, BAER, Maria R, MEILLER, Timothy, DIMOPOULOS, Meletios A

“…To evaluate the natural history of bisphosphonate-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma. Ninety-seven patients with myeloma…”
Get full text

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD" by Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Hatjiharissi, Evdoxia, Katodritou, Eirini, Eleutherakis-Papaiakovou, Evangelos, Verrou, Evgenia, Gavriatopoulou, Maria, Leonidakis, Alexandros, Manousou, Kyriaki, Delimpasi, Sosana, Malandrakis, Panagiotis, Kyrtsonis, Marie-Christine, Papaioannou, Maria, Symeonidis, Argiris, Dimopoulos, Meletios-Athanasios

“…Biomarkers of bone turnover in serum are suggestive of bone dynamics during treatment in multiple myeloma (MM). We evaluated the role of daratumumab on bone…”
Get full text

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE‐TREATED WITH A LENALIDOMIDE‐BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY by Terpos, Evangelos, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Dialoupi, Ioanna, Verrou, Evgenia, Manousou, Kyriaki, Gkolfinopoulos, Stavros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A.

Get full text

Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin? by Verrou, Evgenia, Tsirou, Kyriaki, Karampatzakis, Nikolaos, Triantafyllou, Theodora, Sevastoudi, Aggeliki, Grigoriadou, Georgia I., Konstantinidou, Pavlina, Panagiotidis, Panagiotis, Katodritou, Eirini

“…Herein we present a rare case of two brothers diagnosed with CML four years apart. Importantly, our case of CML occurrence among siblings is the fifth one…”
Get full text

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI‐MYELOMA TREATMENTS ON POST‐ PROGRESSION OUTCOMES IN THE REAL‐WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE by Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis‐Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Labropoulou, Vasiliki, Pouli, Anastasia, Roussou, Maria, Gavriatopoulou, Maria, Verrou, Evgenia, Dimopoulos, Meletios A., Terpos, Evangelos

Get full text

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE by Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Fotiou, Despina, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis‐Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Pouli, Anastasia, Migkou, Magdalini, Gavriatopoulou, Maria, Verrou, Evgenia, Christine Kyrtsonis, Marie, Dimopoulos, Meletios A., Terpos, Evangelos

Get full text

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration by Terpos, Evangelos, Katodritou, Eirini, Tsiftsakis, Evangelos, Kastritis, Efstathios, Christoulas, Dimitrios, Pouli, Anastasia, Michalis, Eurydiki, Verrou, Evgenia, Anargyrou, Konstantinos, Tsionos, Konstantinos, Dimopoulos, Meletios A, Zervas, Konstantinos

“…On behalf of the Greek Myeloma Study Group Correspondence: Evangelos Terpos, Department of Hematology and Medical Research, 251 General Air Force Hospital, 3…”
Get full text

Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response by Hadjiaggelidou, Christina, Vadikolia, Chrysanthi, Verrou, Evgenia, Yiannaki, Efthalia, Triantafyllou, Theodora, Palaska, Vasiliki, Keramidioti, Konstantina, Tsirou, Kyriaki, Papanikolaou, Asimina, Markala, Dimitra, Konstantinidou, Pavlina, Katodritou, Eirini

Get full text

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? by Katodritou, Eirini, Verrou, Evgenia, Gastari, Vassiliki, Hadjiaggelidou, Christina, Terpos, Evangelos, Zervas, Konstantinos

“…Abstract Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasias. Its special biological characteristics may play an important role…”
Get full text

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients by Zervas, Kostas, Verrou, Evgenia, Teleioudis, Zisis, Vahtsevanos, Konstantinos, Banti, Anastasia, Mihou, Dimitra, Krikelis, Dimitris, Terpos, Evangelos

“…Summary The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only…”
Get full text

A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia by Hadjiaggelidou, Christina, Douganiotis, George, Tsirou, Kyriaki, Verrou, Evgenia, Triantafyllou, Theodora, Keramidioti, Konstantina, Konstantinidou, Pavlina, Katodritou, Eirini

Get full text

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study by Terpos, Evangelos, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Dialoupi, Ioanna, Verrou, Evgenia, Leonidakis, Alexandros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A.

“…Introduction The use of lenalidomide in frontline therapy for patients (pts) with newly diagnosed multiple myeloma (NDMM) has increased the number of pts who…”
Get full text

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA by Terpos, Evangelos, Ntanasis‐Stathopoulos, Ioannis, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Malandrakis, Panagiotis, Verrou, Evgenia, Golfinopoulos, Stavros, Migkou, Magdalini, Manousou, Kyriaki, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A.

“…The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple myeloma (MM) has increased the number of those who become refractory to…”
Get full text

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study by Terpos, Evangelos, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Dialoupi, Ioanna, Verrou, Evgenia, Leonidakis, Alexandros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A

“…Introduction: Lenalidomide-based regimens are currently among the standard-of-care treatment options for newly diagnosed patients with multiple myeloma NDMM)…”
Get full text

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group by Katodritou, Eirini, Dalampira, Dimitra, Delimpasi, Sosana, Ntanasis-Stathopoulos, Ioannis, Karaolidou, Frini, Gkioka, Annita Ioanna, Labropoulou, Vasiliki, Spanoudakis, Emmanouil, Triantafyllou, Theodora, Kotsopoulou, Maria, Michalis, Eyrydiki, Vadikolia, Chrysanthi, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Michael, Michael, Daiou, Aikaterini, Pentidou, Aikaterini, Kostopoulos, Ioannis V, Palaska, Vasiliki, Gavriatopoulou, Maria, Kyrtsonis, Marie-Christine, Verrou, Evgenia, Kastritis, Efstathios, Dimopoulos, Meletios A., Terpos, Evangelos

“…Central Nervous System Multiple Myeloma (CNS-MM) is a rare but aggressive complication of MM, and its treatment remains an unmet clinical need. Herein we…”
Get full text

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study by Terpos, Evangelos, Kastritis, Efstathios, Hatjiharissi, Evdoxia, Katodritou, Eirini, Eleutherakis Papaiakovou, Evangelos, Verrou, Evgenia, Gavriatopoulou, Maria, Leonidakis, Alexandros, Ntanasis-Stathopoulos, Ioannis, Delimpasi, Sosana, Kyrtsonis, Marie-Christine, Papaioannou, Maria, Symeonidis, Argiris, Dimopoulos, Meletios A.

“…Introduction: Osteolytic bone disease is the most common clinical feature of multiple myeloma (MM), affecting approximately 80% of patients (pts) at diagnosis…”
Get full text

P-319 Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA by Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Malandrakis, Panagiotis, Verrou, Evgenia, Leonidakis, Alexandros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios

Get full text

Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome by Hadjiaggelidou, Christina, Mandala, Evdokia, Terpos, Evangelos, Yiannaki, Efthalia, Markala, Dimitra, Triantafyllou, Theodora, Papatheodorou, Athanasios, Gkastari, Vassiliki, Verrou, Evgenia, Papanikolaou, Asimina, Konstantinidou, Pavlina, Katodritou, Eirini

“…The exact role of regulatory T cells (Tregs) in multiple myeloma (MM) has not been yet determined. Data regarding alterations of Tregs during therapy with…”
Get full text